Case report on asciminib plus ponatinib or axitinib in CML relapse with B lymphoblastic blast crisis
New combo drug stops leukemia that fought back against two drugs
This case report describes a single CML patient who relapsed with B lymphoblastic blast crisis harboring a T315I mutation and a novel e6a3 B…
A new three-drug mix stops a tough leukemia that grew stronger after two drugs failed to control it.
Ponatinib in CP-CML resistant to prior TKI or T315I mutation showed molecular response at Month 12
Ponatinib doses show early signs in resistant chronic myeloid leukemia patients
This Phase 2 study evaluated ponatinib in 283 participants with chronic-phase chronic myeloid leukemia (CP-CML) resistant to prior tyrosine-…
Ponatinib at three daily doses showed early signs of helping resistant chronic myeloid leukemia patients reach a key molecular response goal…